NCT02685293: A reported trial by Pearl Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02685293 |
|---|---|
| Title | A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 9, 2016 |
| Completion date | June 6, 2018 |
| Required reporting date | June 6, 2019, midnight |
| Actual reporting date | June 6, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |